NASDAQ: IMNMImmunome Inc Stock Ownership - Who owns Immunome?
Insider buying vs selling
Have Immunome Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Isaac Barchas | Director | 2026-08-12 | 11,048 | $27.25 | $301.06kSell |
| Isaac Barchas | Director | 2026-08-11 | 62,291 | $26.23 | $1.63MSell |
| Isaac Barchas | Director | 2026-08-10 | 10,125 | $26.07 | $263.96kSell |
| Isaac Barchas | Director | 2026-08-07 | 15,248 | $26.06 | $397.36kSell |
| Isaac Barchas | Director | 2026-08-06 | 20,840 | $26.06 | $543.09kSell |
| Kinney Horn | CXO | 2026-08-04 | 90,616 | $25.09 | $2.27MSell |
| Kinney Horn | CXO | 2026-08-04 | 40,250 | $10.60 | $426.65kBuy |
| Kinney Horn | CXO | 2026-08-04 | 50,366 | $12.92 | $650.73kBuy |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-07 | 1,092 | $25.00 | $27.30kSell |
| Isaac Barchas | Director | 2026-07-07 | 16,906 | $24.20 | $409.13kSell |
IMNM insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when IMNM insiders and whales buy or sell their stock.
IMNM Shareholders
What type of owners hold Immunome Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Michael Rapp | 1.13% | 1,279,914 | $34.25M | Insider |
| I. Wistar Morris Iii | 0.81% | 920,939 | $24.64M | Insider |
| Clay B. Siegall | 0.77% | 870,704 | $23.30M | Insider |
| Isaac Barchas | 0.45% | 509,219 | $13.63M | Insider |
| Philip Wagenheim | 0.30% | 341,147 | $9.13M | Insider |
| Max Rosett | 0.09% | 101,287 | $2.71M | Insider |
| Philip Tsai | 0.07% | 81,550 | $2.18M | Insider |
| Robert Lechleider | 0.06% | 69,805 | $1.87M | Insider |
| John L. Lamattina | 0.06% | 66,953 | $1.79M | Insider |
| Jack Higgins | 0.06% | 63,250 | $1.69M | Insider |
IMNM vs Biotech Stocks
Immunome Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.